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Background: Data on lipid profile abnormalities among patients receiving highly active antiretroviral treatment in
Ethiopia are very limited. The aim of this study was to determine the prevalence of dyslipidemia and characteristics
of lipid profiles among patients living with human immunodeficiency virus (HIV) using first-line highly active
antiretroviral therapy (HAART) in Southern Ethiopia.
Methods: This cross sectional comparative group study was conducted between March and May 2012, and
included 113 HIV infected patients treated for a minimum of one year with first-line HAART regimens that included
Efavirenz and Nevirapine (HAART group) and others 113 who had never received HAART (pre-HAART group). Serum
lipid profiles were determined after overnight fasting and dyslipidemia was assessed according to the United State
National Cholesterol Education program-III guideline. For statistical analysis Chi-square, student’s t-test, and logistic
regression were used using Statistical Package for Social Sciences (SPSS) Version 20.
Result: Ninety-three (82.3%) of HAART and 87 (76.9%) pre-HAART patients had at least one laboratory abnormality,
which is compatible with a diagnosis of dyslipidemia. Total cholesterol ≥ 200 mg/dl occurred in 43.4% of HAART
and 15.9% pre-HAART patients (p=<0.0001), whereas HDL-cholesterol below 40 mg/dl occurred in 43.4% and in
63.7% respectively, (p=0.002). The LDL-cholesterol ≥ 130 mg/dl occurred in 33.6% of HAART and 15% pre-HAART
patients (p=0.001), while triglycerides ≥ 150 mg/dl occurred in 55.8% and 31.0% respectively, (p=0.001). Receiving
of HAART was significantly and positively associated with raised total cholesterol, LDL-cholesterol, and triglycerides.
The adjusted odds ratio (95% CI) of HAART-treated vs. pre-HAART was 3.80 (1.34-6.55) for total cholesterol ≥ 200
mg/dl; 2.64 (1.31-5.32) for LDL- cholesterol ≥ 130 mg/dl and 2.50 (1.41-4.42) for triglycerides ≥150 mg/dl.
Conclusion: Use of first-line antiretroviral therapy regimens that contain Efavirenz and Nevirapine were associated
with raised total cholesterol, LDL-cholesterol, and triglycerides, an established atherogenic lipid profiles. Lipid
profiles should be performed at baseline before commencement of antiretroviral therapy and then periodically
through treatment follow-up to monitor any rising trends.
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In 2011, an estimated 34 million people were living with
human immunodeficiency virus /acquired immunodefi-
ciency syndrome (HIV/AIDS) worldwide; of them 22.9
million were living in Sub-Saharan Africa. About 1.2 mil-
lion people were estimated to be living with HIV in Ethi-
opia [1].The introduction of highly active antiretroviral
therapy (HAART) has led to a marked reduction in AIDS-
related morbidity and mortality [2]. Since its introduction
patients have started to live longer, however co-morbid
problems have been emerged. Dyslipidemia, insulin resist-
ance, and diabetes are some of metabolic complications of
long-term use of HAART [3]. The characteristics of dysli-
pidemia in HIV-infected patients receiving HAART
includes, elevated level of total cholesterol (TC), LDL-
cholesterol (LDL-c), triglycerides (TG), and decreased
HDL-cholesterol (HDL-c), include with severe hypertrigly-
ceridemia in some patients [4]. Some antiretroviral drugs,
such as stavudine (d4T) [5], and protease inhibitors (PIs)
[6], increase the blood levels of TC, LDL-c, and TGs with
variable effects on levels of HDL-c. Nevirapine (NVP) use
is associated with increases in LDL-c [7], whereas
increases in TC and TG are observed with use of efavirenz
(EFV), particularly with longer duration of therapy [8].
Therefore, the use of HAART raises concerning metabolic
disorders and cardiovascular risk in HIV infected patients
who now present an extended life expectancy [9]. The
prevalence of dyslipidemia in resource-limited settings has
not been well characterized and current World Health
Organization (WHO) antiretroviral therapy (ART) guide-
lines do not include a recommendation that lipid monitor-
ing should be conducted in patients receiving first-line
HAART [10]. In addition, evidences in support of dyslipi-
demia associated with first-line HAART that include EFV
and NVP in Sub-Sahara African countries are scarce
[11,12].The aim of the present study was to determine the
prevalence of dyslipidemia and characteristics of lipid pro-
files among people living with HIV infection receiving
first-line HAART in Southern Ethiopia.
Methods
Study setting and study population
This was a cross-sectional comparative group study. Sub-
jects were recruited between March 2012 and May 2012
at ART clinic of Hawassa University Referral Hospital.
Two groups of participants were selected for this study.
The first group included HIV-infected individuals who
had been receiving WHO recommended first-line
HAART for a minimum of one year (HAART group). Par-
ticipants used first-line HAART regimens that included
nucleoside reverse transcriptase inhibitors (NRTIs): lami-
vudine (3TC), ZDV, or d4T, and non-nucleoside reverse
transcriptase inhibitors (NNRTIs): NVP or EFV. Patients
who had had their therapy regimens changed duringfollow-up were not included. The second group was pre-
tested and confirmed HIV-positive individuals who were
not yet getting HAART. All participants included were
≥18 years of age and HAART treated group to have a
good ART adherence (adherence rate ≥ 95%). A good ad-
herence is defined by missing < 2 dose of 30 doses or < 3
dose of 60 doses; and it was adopted from Ethiopian
Federal Ministry of Health, HIV Care/ART follow-up
form. Participants receiving lipid altering therapies, preg-
nant women, known diabetes mellitus patients and renal
failures were excluded.
Assessments and measurements
For all participants, data were collected on the socio-
demographic informations along with body mass index,
medical history including diabetes mellitus, renal fail-
ures, use of drugs that alter lipid profiles, and current
use of anti-TB drugs. CD4+ lymphocyte count was done
by using flow cytometry instrument (Becton Dickinson,
CA, USA). Blood sample was collected from each par-
ticipant after a 12 hour overnight fast and centrifuged at
3000 cycles/ minute, and then serum was obtained for
lipid profiles. Fasting serum TC and TG were assayed by
enzymatic method (Linear chemicals, Montgat, Spain).
Serum HDL-c determined by enzymatic method after a
selective precipitation of apolipoprotein containing lipo-
proteins (very low density lipoprotein, LDL-c, and apoli-
poprotein a (Lpa) by phosphotungstic acid/MgCl2
(Linear chemicals, Montgat, Spain). LDL-c was assessed
by enzymatic method after precipitation of LDL by
polyvinyl sulfate (Linear chemicals, Montgat, Spain) and
then LDL-c was calculated by subtracting the super-
natant cholesterol fractions from the TC of the sample.
And also the TC/HDL-c ratio was calculated.
Finally dyslipidemia was defined as TC ≥ 200 mg/dl,
HDL-c < 40 mg/dl, LDL-c ≥ 130 mg/dl, TG ≥ 150 mg/dl
and TC/HDL-c ratio ≥ 5 by the United States National
Cholesterol Education Program, Adult Treatment Panel
(NCEP-ATP) III guidelines [13].
Statistical analysis
The estimation of the sample size was based on the differ-
ence between proportions and the following parameters
were considered: alpha (α) = 5%, beta (β) = 10 % and
power = 90%. Concerning dyslipidemia, we considered
frequencies of LDL-c ≥130 mg/dl, which was 21% for the
group of individuals with HIV/AIDS without HAART
treatment [14]; and 40.8% for patients receiving HAART
treatment [15]. With these parameters, the sample size
calculated was 230 participants (115 pre-HAART and 115
HAART-treated patients).Data entry and Database man-
agement was completed using EPI-INFO 2002. Statistical
analyses were done using Statistical Package for Social
Sciences (SPSS) Version 20. Chi-square test was used to
Table 1 Characteristics of study population by HAART





Gender = Female, n (%) 75 (66.4) 72 (63.7)
Male, n (%) 38 (33.6) 41 (36.3)
Age, (years), mean ± SD 37.2 ( 8.7) 33.7 (8.3)**
18–30 years, n (%) 26 (23) 49 (43.4)
31–40 years, n (%) 59 (52.2) 47(41.6)
41–50 years, n (%) 21 (18.6) 12 (10.6)
>50 years, n (%) 7 (6.2) 5 (4.4)
BMI (Kg/m2), mean ± SD 22.3 (4.1) 21.5 ( 3.9)
<18 Kg/m2, n (%) 8 (7) 14 (12.4)
18–25 Kg/m2, n (%) 82 (72.6) 84 (74.3)
>25 Kg/m2, n (%) 23 (20.4) 15 (13.3)
CD4+ count (cells/mm3),
mean ± SD
460 (221) 356 (216.7) ***
< 200 cells/mm3, n (%) 16 (14.2) 29 (25.7)
200–400 cells/mm3, n (%) 32 (28.3) 44 (38.9)
> 400 cells/mm3, n (%) 65 (57.5) 40 (35.4)
Duration of HAART, mean ±SD 49.4 (16.5) –
12–24 months, n (%) 10 (8.8) –
24–36 months, n (%) 18 (15.9) –
36–48 months, n (%) 27 (23.9) –
48–60 months, n (%) 24 (21.2) –
> 60 years, n (%) 34 (30.1) –
Current anti-TB users, n (%) 0 4 (3.5)
Current smoking, n (%) 6 (5.3) 7 (6.2)
Past smoking, n (%) 15 (13.3) 13 (11.5)
BMI, body mass index; HAART, highly active antiretroviral therapy; mo, month;
TB, tuberculosis; SD, standard deviation; ** p-value < 0.01; *** p-value < 0.001.
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t-test was applied to assess differences between two
means. Logistic regression was also used to determine the
association of independent factors (age, gender, and treat-
ment status, type of treatment, current CD4 counts, and
history of smoking, body mass index and current use of
anti-TB drugs) with abnormal level of each lipid profile.
P-value less than 0.05 considered as statistically significant
at 95% confidence interval (CI).
Ethical consideration
The study was approved by the ethical review committee
of School of Biomedical and Laboratory Sciences, Uni-
versity of Gondar. All individuals participated in the
study provided their informed consent.
Results
General characteristics of study participants
Total number of participants enrolled in the study was
226, with 79 (35%) males and 147 (65%) females. Two
groups were studied: the first group 113 HIV-infected
patients (38 (33.6%) males, 75 (66.4%) females) were cur-
rently receiving HAART treatment; the second group 113
patients (41 (36.3%) males, 72 (63.7%) females) were pre-
HAART. The age of individuals who were on HAART
was 37.2 ± 8.7 while that of pre-HAART was 33.7 ±8.3
years and the age difference was significantly different
(Table 1). First-line HAART regimens were a combina-
tions of 2NRTI and 1NNRTI. All regimens included 3TC.
HAART patients had been on treatment for a mean of
49.4 months (standard deviation: 16.5). The number of
patients on ZDV/3TC/EFV, and ZDV/3TC/NVP regimens
were 22 (19.5%) and 36 (31.8%) respectively, while those
on d4T/3TC/EFV, and d4T/3TC/NVP regimens were 24
(21.2%) and 31 (27.4%) respectively. Accordingly, 58
(51.3%) patients were on ZDV, 55 (48.7%) were on d4T, 46
(40.7%) were on EFV, and 67 (59.3%) were on NVP.
Dyslipidemia and characteristics of lipid profiles
Ninety-three (82.3%) of HAART treated and 87 (76.9%)
pre-HAART patients had at least one laboratory abnor-
mality, which is compatible with a diagnosis of dyslipide-
mia (Figure 1). The prevalence of TC ≥ 200 mg/dl, LDL-c
≥130 mg/dl and TG ≥150 mg/dl were significantly higher
in HAART group when compared to pre-HAART group.
The prevalence of HDL-c below 40 mg/dl was signifi-
cantly higher in pre-HAART group when compared to
those on HAART. However, there was no significant dif-
ference in TC/HDL-c ratio between HAART treated and
pre-HAART patients (Table 2).
Dyslipidemia and first-line HAART
No significant difference observed in lipid profile
derangements between patients receiving ZDV whencompared to those on d4T; and patients treated with
EFV when compared to those treated with NVP (Table 3
and Table 4). In addition, no significant difference
observed in lipid derangements between HAART treated
males and females; however, the proportion of raised
LDL-c is slightly higher in females when compared to
males (Figure 2).Dyslipidemia and risk factors
Multivariate analysis was adjusted for potential con-
founding factors such as age, sex, current history of
smoking, past history of smoking, BMI, CD4+cells,
current use of anti-TB drugs, and HAART treatment.
Receiving of HAART was significantly and positively
associated with raised TC, LDL-c, and TG. The adjusted
odds ratio (95% CI) of HAART-treated vs. pre-HAART


























Figure 1 Category of dyslipidemia among study population by HAART status in Hawassa, Southern Ethiopia. Number of patients in
HAART group was 113 and in pre-HAART group were113; number of patients with single lipid profile abnormal in pre-HAART group and HAART
group were respectively, 50 and 26; and number of patients with mixed lipid profiles abnormal in pre-HAART group and HAART group were
respectively, 37 and 67; HAART, highly active antiretroviral therapy; (single lipid profile abnormal means only one lipid parameter is abnormal and
mixed lipid profile abnormal means more than one lipid parameters abnormal within a single individual).
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150 mg/dl. However, antiretroviral therapy was not posi-
tively associated with decreased of HDL-cholesterol
(Table 5).
Univariate and multivariate analysis were also applied
to assess independent risk factors for each abnormal
lipid profile in the subgroup of 113 HAART treatedTable 2 Serum lipid profiles of study population by





Total cholesterol, mean ± SD 199.6 (51.5) 155.4 (44) ***
< 200mg/dl 64 (56.6%) 95 (84.1%)
≥ 200mg/dl 49 (43.4%) 18 (15.9%) ***
HDL-cholesterol, mean ± SD 43.2 (14.3) 33.3 (12.8 ) ***
< 40mg/dl 49 (43.4%) 72 (63.7%) **
≥ 40mg/dl 64 (56.6%) 41 (36.3%)
LDL-cholesterol, mean ± SD 119.3 (43) 97.3 (36.2) ***
< 130mg/dl 75 (66.4%) 96 (85%)
≥ 130mg/dl 38 (33.6%) 17 (15.0%) **
Triglycerides, mean ± SD 204 (143) 138 (76 ) ***
< 150mg/dl 50 (44.2%) 78 (69%)
≥150mg/dl 63 (55.8%) 35 (31.0%) ***
TC/HDL-c ratio, mean ± SD 5.2 (2.4) 5.3 (2.6)
< 5 62 (54.9%) 64 (56.6%)
≥ 5 51 (45.1%) 49 (43.4%)
HAART, highly active antiretroviral therapy; TC, total cholesterol; HDL,
high-density lipoprotein; LDL, low- density lipoprotein; SD, standard deviation;
** p-value < 0.01; *** p-value <0.001.patients. In these both models, age was the risk factor
of raised TC and decreased HDL-c; and BMI was the
risk factor of raised TC in HAART treated patients
(Table 6).
Discussion
The aim of this cross-sectional study carried out in a re-
source limited East African setting was to assess the
prevalence of dyslipidemia (lipid profile derangements)
among HIV-infected patients receiving first-line HAART
that include NNRTIs. We found that CD4 cell count in
the HAART group was significantly different from the
pre-HAART group, thus showing the effects of HAART
in improving the immunological properties of the
subjects.
In the present study, the majority of HAART
patients (82.3%) had at least one laboratory abnormality,
which is compatible with a diagnosis of dyslipidemiaTable 3 Prevalence of abnormal lipid profiles among
patients treated with NRTIs based first-line antiretrovirals






TC ≥ 200 mg/dl 25 (43.1) 24 (43.6) 0.95
HDL-c < 40 mg/dl 24 (41.4) 25 (45.4) 0.66
LDL-c ≥ 130 mg/dl 20 (34.5) 18 (32.7) 0.84
TG ≥ 150 mg/dl 32 (55.2) 31 (56.4) 0.41
TC/HDL-c ratio ≥5 24 (41.4) 27 (49.1) 0.89
TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c,
low-density lipoprotein cholesterol; TG, triglyceride; ZDV, Zidovudine; d4T,
stavudine; p, significance level.
Table 4 Prevalence of abnormal lipid profiles among
patients treated with NNRTIs based first-line






TC > 200 mg/dl 18 (39.1) 31 (46.3) 0.45
HDL-c < 40 mg/dl 22 (47.8) 27 (40.3) 0.43
LDL-c > 130 mg/dl 14 (30.4) 24 (35.8) 0.55
TG > 150 mg/dl 25 (54.3) 38 (56.7) 0.80
TC/HDL ratio >5 22 (47.8) 29 (43.3) 0.63
TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c,
low-density lipoprotein cholesterol; TG, triglyceride; EFV, Efavirenz; NVP,
Nevirapine; p, significance level.
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the proportions of raised TC, LDL-c and TG were
significantly higher in HAART group when compared
to pre-HAART group. The proportion of HDL-c
below 40 mg/dl was significantly higher in the pre-
HAART group when compared to those on HAART,
thus indicating the effects of HAART treatment in
raising the lipid profiles, in addition to the restoration
of health. However, there was no significant difference
between treated group and non-treated group regard-
ing TC/HDL-c ratio, this because increases in TC
were counterbalanced by HDL-c improvement. The
described raised lipid profiles (TC, LDL-c and TG),
are atherogenic [13,16,17], and suggest a potential risk
for the development of cardiovascular diseases in a































Figure 2 Gender and abnormal lipid profiles among first-line HAART
females (n=75); TC, total cholesterol; HDL-c, high-density lipoprotein cholesThe association between lipid derangements and
HAART has been mainly depicted for regimens that
contain PIs [6,18]. In addition, NNRTIs derange lipid
profiles during therapy [7,8]. However, supportive evi-
dences are very scarce in Sub-Sahara African countries
concerning lipid derangements in patients receiving
NNRTs including regimens [11,12]. We found that the
prevalence of raised TC in HAART group was (43.4%).
This prevalence rate is higher than the study reported
from a resource poor West African setting [19]. The
prevalence rate in this study was 4.5%. However, in this
study, the cutoff limit was >210 mg/dl; and this value
is higher than that of NCEP-ATP III guidelines, as used
in our study. Based on HDL-c cut off value, the preva-
lence of HDL-c in our treatment group was 43.4%.
This is comparable with the prevalence rate reported
from Spain [20]. However, it is higher than the preva-
lence reported from rural South India [21]. The preva-
lence rate in this study was 24.8%. The prevalence of
raised LDL-c in our HAART group was 33.6%. It is
similar with the prevalence reported from India [21].
We found that the prevalence of raised TG in HAART
group was 55.8%. This is not in line with the preva-
lence reported from Cameroon [14], Kenya [15], and
India [21]. The prevalence rates in these three studies
were respectively, 43.5%, 22.5%, and 42.1%. However,
there are suggestions that the magnitude of lipid profile
derangements induced by first-line HAART could show
variation with duration of treatment, across populations
and setting.
The reports from rural South India and Brazil indi-
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treated patients in Hawassa, Southern Ethiopia. [Males (n=38);
terol; LDL-c, low-density lipoprotein cholesterol; TG, triglyceride].
Table 5 Associations HAART and other variables with dyslipidemia among HIV-infected patients in Hawassa, Southern
Ethiopia
Explanatory variable Outcome variables
TC ≥ 200 mg/dl HDL< 40 mg/dl LDL ≥ 130 mg/dl TG ≥ 150 mg/dl
AOR (95% CI) AOR (95% CI) AOR (95% CI) AOR (95% CI)
CD4+cells ≥200/mm3* 1.00 1.00 1.00 1.00
CD4+cells < 200/mm3 0.91 (0.39-2.10) 1.95 (0.94-4.07) 0.89 (0.37-2.15) 0.87 (0.42-1.80)
P-value 0.82 0.07 0.79 0.71
BMI ≤ 25 Kg/m2* 1.00 1.00 1.00 1.00
BMI > 25 Kg/m2 2.96 (1.35-6.49) 0.55 (0.26-1.18) 2.66 (1.17-5.59) 2.82 (1.31-6.07)
P-value 0.007 0.13 0.02 0.008
Gender = Female* 1.00 1.00 1.00 1.00
Male 0.71 (0.32-1.57) 0.73 (0.38-1.42) 0.53 (0.22-1.25) 1.44 (0.74-2.82)
P-value 0.4 0.36 0.15 0.28
Age ≤ 40 years* 1.00 1.00 1.00 1.00
Age > 40 years 3.04 (1.41-6.55) 2.64 (1.23-5.69) 3.28 (1.48-7.30) 1.47 (0.71-3.05)
P-value 0.004 0.01 0.004 0.29
Pre-HAART* 1.00 1.00 1.00 1.00
HAART 3.80 (1.34-7.44) 0.44 (0.25-0.78) 2.64 (1.31-5.32) 2.50 (1.41-4.42)
P-value <0.0001 0.005 0.006 0.002
No smoking* 1.00 1.00 1.00 1.00
Current smoking 0.90 (0.20-4.00) 2.13 (0.57-8.01) 0.32 (0.36-2.82) 0.75 (0.21-2.64)
P-value 0.89 0.26 0.3 0.65
No smoking* 1.00 1.00 1.00 1.00
Past smoking 0.77 (0.25-2.33) 1.46 (0.57-3.75) 0.56 (0.16-1.91) 0.67 (0.26-1.75)
P-value 0.64 0.43 0.35 0.42
No ant-TB drug * 1.00 1.00 1.00 1.00
Ant-TB drug 1.85(0.17-20.51) NA 1.74(0.1519.82) NA
P-value 0.62 NA 0.65 NA
HAART, highly active antiretroviral therapy; AOR, adjusted odds ratio; CI, confidence interval; BMI, body mass index; TC, total cholesterol; HDL, high-density
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride; NA, not available; p, significance level; TB, tuberculosis; * Reference category.
Tadewos et al. AIDS Research and Therapy 2012, 9:31 Page 6 of 8
http://www.aidsrestherapy.com/content/9/1/31were higher among patients received d4T when com-
pared to other NRTIs [21,22]. We found no difference
in lipid derangements when patients received d4T com-
pared to those received ZDV. This finding is similar
with the reports from Uganda, and Cameroon [11,14].
The randomized trial report of 2 non-nucleosides
(2NN) indicated that patients on NVP group had sig-
nificantly improved HDL-c concentration and had rela-
tively low lipid profile derangements when compared to
those on EFV [23]. In line with the reports from rural
Uganda [11], Cameroon [14] and India [24], we found
no significant difference in lipid profile of patients on
EFV compared to those on NVP. In the present study,
the raised TC and LDL-c were significantly and posi-
tively associated with the use of HAART treatment, and
the findings are in line with the study conducted in
Cameroon [14].Limitations of the study
Comprehensive cardiovascular risk stratifications were
not assessed in this study. However, the increased risk of
cardiovascular diseases associated with described lipid
derangements is well known [25-27], and long term use
of first-line HAART may have an impact on cardiovas-
cular system. The other limitations were the cross-
sectional nature of the study, small number of male
participants, and lack of HIV negative controls.
Conclusion
Our study indicates HIV-infected patients receiving
WHO-recommended first-line HAART that include Efa-
virenz and Nevirapine have a high prevalence of lipid
profile derangements when compared to those non-
treated HIV-infected patients. Uses of first-line HAART
regimens are significantly associated with atherogenic





TC ≥ 200 mg/dl HDL-c < 40 mg/dl LDL-c ≥ 130mg/dl TG ≥150 mg/dl
BMI > 25kg/m2
UOR (95% CI) 3.09 (1.18-8.05)* 0.50 (0.19-1.33) 2.68 (1.05-6.85)* 2.71 (0.98-7.50)
AOR (95% CI) 3.21 (1.16-8.91)* 0.49 (0.17-1.39) 2.44 (0.91-6.51) 2.92 (0.99-8.44)
Gender (male)
UOR (95% CI) 0.93 (0.42-2.04) 1.28 (0.58-2.80) 0.49 (0.20-1.19) 1.14 (0.52-2.51)
AOR (95% CI) 0.68 (0.23-2.04) 0.69 (0.24-1.96) 0.43 (0.13-1.46) 1.09 (0.40-2.99)
Age > 40 years
UOR (95% CI) 3.13 (1.28-7.63)* 3.14 (1.29-7.64)* 2.08 (0.86-5.00) 1.97 (0.80-4.84)
AOR (95% CI) 4.43 (1.54-12.72)** 4.22 (1.46-12.16)** 4.28 (1.41-12.97)* 2.12 (0.77-5.82)
HAART ≤ 2 years
UOR (95% CI) 0.95 (0.24-3.75) 0.35 (0.08-1.49) 1.85 (0.37-9.39) 1.00 (0.26-3.97)
AOR (95% CI) 0.76 (0.16-3.66) 0.30 (0.06-1.47) 1.35 (0.22-8.20) 0.92 (0.21-4.09)
Current smoking
UOR (95% CI) 0.64 (0.11-3.64) 1.33 (0.26-6.87) 0.38 (0.04-3.36) 0.78 (0.15-4.06)
AOR (95% CI) 0.77 (0.12-5.79) 0.70 (0.10-4.80) 0.51 (0.04-5.82) 0.78 (0.12-5.04)
Past smoking
UOR (95% CI) 1.17 (0.39-3.47) 1.17 (0.39-3.47) 0.45 (0.12-1.70) 1.22 (0.40-3.70)
AOR (95% CI) 0.82 (0.20-3.34) 0.62 (0.16-2.45) 0.39 (0.08-1.98) 0.88 (0.23-3.40)
d4T
UOR (95% CI) 1.02 (0.48-2.15) 1.18 (0.56-2.49) 0.92 (0.42-2.02 1.05 (0.50-2.21)
AOR (95% CI) 1.29 (0.57-2.93) 1.41 (0.63-3.16) 1.22 (0.52-2.85) 1.17 (0.53-2.58)
EFV
UOR(95% CI) 0.75 (0.35-1.60) 1.36 (0.64-2.89) 0.78 (0.35-1.75) 0.91 (0.43-1.93)
AOR (95% CI) 0.77 (0.33-1.79) 1.36 (0.60 3.12) 0.91 (0.37-2.22) 0.97 (0.43-2.18)
HAART, highly active antiretroviral therapy therapy; UOR, un adjusted odds ratio; AOR, adjusted odds ratio; CI, confidence interval; TC, total cholesterol; HDL-c,
high-density lipoprotein cholesterol; LDL-c, low- density lipoprotein cholesterol; TG, triglyceride; d4T Stavudine; BMI, body mass index; EFV, Efavirenz; * p-value
< 0.05; ** p-value < 0.01. Reference category: BMI ≤ 25 Kg/m2, Females, Age ≤ 40 years, no smoking, Nevirapine group, Zidovudine group; HAART treatment
>2years.
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need to assess lipid profiles at baseline before initiation
of HAART treatment and lipid profile monitoring dur-
ing therapy to monitor any rising trends. Additionally,
the results also recommend implementation of well-
controlled cohort studies for the evaluation of long-term
effects of HAART treatment on lipid profiles.
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